Shenwen Huang

No bio available.

Financial relationships

  • Attribution:
    Spouse or Partner
    Type of financial relationship:
    Stock
    Ineligible company:
    CytoDyn, Inc
    Topic:
    leronlimab, a monoclonal antibody CCR5 receptor antagonist
    Date added:
    02/23/2026
    Date updated:
    02/23/2026
  • Attribution:
    Spouse or Partner
    Type of financial relationship:
    Stock
    Ineligible company:
    Crispr Therapeutics AG
    Topic:
    CRISPR
    Date added:
    02/23/2026
    Date updated:
    02/23/2026
  • Attribution:
    Spouse or Partner
    Type of financial relationship:
    Stock
    Ineligible company:
    Viking Therapeutics Inc
    Topic:
    pharmaceutical development for metabolic disorders
    Date added:
    02/23/2026
    Date updated:
    02/23/2026
  • Attribution:
    Spouse or Partner
    Type of financial relationship:
    Stock
    Ineligible company:
    Cytokinetics, Inc.
    Topic:
    small molecules to activate and inhibit muscles
    Date added:
    02/23/2026
    Date updated:
    02/23/2026
Return to April 17, 2026 10th Annual National Neuroscience Review Conference